Recent Updates
Recently added Catalysts
NBTX Positive Sentiment Score: 70/100

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

Key Takeaway: Nanobiotix, a late-stage biotechnology company focused on innovative cancer treatments, announced its participation in two upcoming investor conferences in February and March 2025. The events will feature key company executives, including the CEO and CFO, who will discuss the company's nanoparticle-based therapeutic approaches. These presentations aim to increase investor awareness and highlight the company's commitment to advancing treatment possibilities for major diseases. The webcasts will be available for viewing post-event on the company's investor relations page.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in notable investor conferences to enhance visibility.
  • Management includes key leaders presenting cutting-edge technology.
  • Focus on pioneering nanoparticle-based approaches for cancer treatment.

Full Press Release Details

PARIS and CAMBRIDGE, Mass., Jan. 29, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences:
Guggenheim SMID Cap Biotech Conference
Date: Thursday, February 6, 2025
Time: 1pm ET / 7pm CET
Location: New York, NY
Presenter: Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
Webcast link: Click here
Leerink Global Healthcare Conference
Date: Wednesday, March 12, 2025
Time: 10:40pm ET / 4:40pm CET
Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
Webcast link: Click here
The fireside chats will be webcast live from the events page of the Investors section of the Company’s website. Replay of the webcast will be available following the event.
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr Global – LifeSci Advisors Kevin Gardner +1 (617) 283-2856 kgardner@lifesciadvisors.com
2025-01-29 -- NBTX -- Feb & Mar Conferences -- FINAL

Attachments

2025-01-29 -- NBTX -- Feb & Mar Conferences -- FINAL...

Frequently Asked Questions

What conferences will Nanobiotix participate in?

Nanobiotix will participate in the Guggenheim SMID Cap Biotech Conference and the Leerink Global Healthcare Conference.

Who will present at the Guggenheim Conference?

Bart van Rhijn, Chief Financial & Business Officer, will present at the Guggenheim Conference.

When is the Leerink Global Healthcare Conference?

The Leerink Global Healthcare Conference is on March 12, 2025, at 10:40 PM ET.

Where is Nanobiotix headquartered?

Nanobiotix is headquartered in Paris, France.

How many patent families does Nanobiotix own?

Nanobiotix owns over 25 patent families related to three nanotechnology platforms.

Last updated: Jan 29, 2025